Skip to content

Effect of growth hormone therapyin obese boys with nonalcoholic fatty liver disease

Effect of growth hormone therapyin obese boys with nonalcoholic fatty liver disease

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100042787
Enrollment
Unknown
Registered
2021-01-28
Start date
2021-01-26
Completion date
Unknown
Last updated
2021-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nonalcoholic fatty liver disease

Interventions

NAFLD group:rhGH theatment
NAFLD group:no theatment

Sponsors

The Second Hospital of Shandong University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: The diagnosis of NAFLD is estimated by ultrasound scan, and the calculation was according to the criteria of The Chinese National Workshop on Fatty Liver and Alcoholic Liver Disease for the Chinese Liver Disease Association. NAFLD was diagnosed upon detection of the presence of at least two of following three characteristic echo patterns: 1) the presence of increased liver echogenicity. 2) diffuse hyperechogenicity of the liver relative to the kidneys. 3) poor visualization of the diaphragm or intrahepatic vessels.

Exclusion criteria

Exclusion criteria: 1) Secondary obesity; 2) Positive hepatitis B surface antigen, positive hepatitis C antibodies or other liver disease such as Wilson's disease or autoimmune hepatitis etc; 3) dDabetes, hypothalamus-pituitary diseases or other disease condition known to affect the GH axis; 4) Children who ever have had alcohol intake, smoked or used drugs which may influence liver function, glucose, lipid metabolism or weight within the 3 months prior to study; 5) Serious infection, systemic disease, and other chronic wasting illnesses; 6) Short stature or growth velocity is less than 5 cm/year.

Design outcomes

Primary

MeasureTime frame
physical examination;Function of GH-IGF-1 axis, pituitary thyroid axis and pituitary adrenal axis; ?????????HbA1C?CRP?TNF-a,IL-6 ?????????HbA1C?CRP?TNF-a,IL-6 Liver function, biochemistry, blood lipid, HbA1c, CRP, TNF- a, IL-6, etc.;MRI of hypothalamus and pituitary;Skeletal Age;

Countries

China

Contacts

Public ContactShuang Liang

The Second Hospital of Shandong University

liangshuang3508@163.com+86 17660082768

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026